Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-05-06
2008-05-06
Tucker, Zachary C. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252020, C514S255050, C544S238000, C544S295000, C544S357000
Reexamination Certificate
active
07368447
ABSTRACT:
The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers.
REFERENCES:
patent: 4894376 (1990-01-01), Morad et al.
patent: 6858614 (2005-02-01), Johnson
patent: 6858615 (2005-02-01), Johnson
patent: 6903105 (2005-06-01), Johnson
patent: 7026325 (2006-04-01), Johnson
patent: 7192958 (2007-03-01), Johnson
patent: 7192960 (2007-03-01), Johnson
patent: 2004/0198744 (2004-10-01), Johnson
patent: 2004/0198745 (2004-10-01), Johnson
patent: 2004/0198746 (2004-10-01), Johnson
patent: 2004/0198747 (2004-10-01), Johnson
patent: 2004/0198748 (2004-10-01), Johnson
patent: 2004/0198749 (2004-10-01), Johnson
patent: 2004/0204424 (2004-10-01), Johnson
patent: 2004/0204425 (2004-10-01), Johnson
patent: 2004/0229884 (2004-11-01), Johnson
patent: 2005/0059676 (2005-03-01), Johnson
patent: 2005/0080091 (2005-04-01), Johnson et al.
patent: 2005/0080092 (2005-04-01), Johnson
patent: 2005/0080093 (2005-04-01), Johnson et al.
patent: 2005/0090505 (2005-04-01), Johnson et al.
patent: 2005/0113388 (2005-05-01), Johnson
patent: 2005/0113389 (2005-05-01), Johnson
patent: 2005/0113390 (2005-05-01), Johnson
patent: 1.525.670 (1968-04-01), None
patent: 1.525.671 (1968-04-01), None
Kellerman, D. “P2Y2 Receptor Agonists” Chest, vol. 121(5), pp. 201S-205S (May 2002 Supplement).
Cragoe, Jr., et al., Journal of Medicinal Chemistry, Jan. 1967, vol. 10, No. 1, pp. 66-75, “Pyrazine Diuretics. II. N-Amidino-3-amino-5-substituted 6-Halopyrazinecarboxamides”.
Kleyman, et al., American Journal of Physiology, 1991, vol. 260, Pt. 1, pp. C271-C276, “Distinct Epitopes on Amiloride. II Variably Restricted Epitopes Defined by Monoclonal Anti-Amiloride Antibodies”.
Cocks, et al., British Journal of Pharmacology, 1988, vol. 95, pp. 67-76, “Amiloride Analogues Cause Endothelium-Dependent Relaxation in the Canine Coronary Artery in Vitro; Possible Role of Na+/Ca2+Exchange”.
Written Opinion of the International Searching Authority, mailed Jan. 31, 2005.
Johnson Michael R.
Molino Bruce F.
Sargent Bruce
Zhang Jianzhong
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
Parion Sciences, Inc.
Tucker Zachary C.
LandOfFree
Capped pyrazinoylguanidine sodium channel blockers does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Capped pyrazinoylguanidine sodium channel blockers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Capped pyrazinoylguanidine sodium channel blockers will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2747718